Triple-Negative Breast Carcinoma — Trials

Triple-Negative Breast Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

950 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 417
Recruiting: 234
Ph III recruiting: 22
Growth YoY: +2.4%
Industry share: 31%
Top sponsor: Fudan University
Termination share: 47.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 1–48 of 48 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07698106	Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC	not yet recruiting	Phase 1 / Phase 2	60	University Health Network, TorontoOTHER	0	Sep 28, 2026	clinicaltrials
NCT07419880	Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer(RECLAIM)	not yet recruiting	Phase 2	46	Fudan UniversityOTHER	1	Sep 25, 2026